Dabrafenib - ≥98%, high purity , CAS No.1195765-45-7, Inhibitor of B-Raf proto-oncogene; serine/threonine kinase

Item Number

D127289

• Synonyms: GSK-2118436A | GSK-2118436 | AKOS024463285 | CCG-264736 | N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide | P06 | Q413328 | Dabrafenib (Free Base) | DB08912 | DABRAFENIB [MI] | GSK2118
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated B
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Inhibitor of B-Raf proto-oncogene; serine/threonine kinase
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
A potent and selective inhibitor of Raf-B protein kinase carrying V600E mutation